Boehringer’s Innovation Strategy Does Not Avoid Areas With Heavy Competition
Executive Summary
BI’s global head of innovation Michel Pairet tells In Vivo that while unmet medical need is the pharma’s R&D priority, its main focus is bringing breakthrough therapy potential to patients, and it is taking aim at competitive spaces like metabolic health and cancer.
You may also be interested in...
BI Prepares For Regulatory Filings After Spevigo Successfully Prevents GPP Flares
The German firm’s Spevigo seems set to dominate the generalized pustular psoriasis market after it reduced the risk of flares in the pivotal EFFISAYIL 2 trial, triggering label expansion plans less than a year after it was approved for flare treatment.
Boehringer/Zealand Dual Agonist Achieves Promising Level Of Weight Loss
Survodutide provides another obesity treatment option, albeit with gastrointestinal side effects that will need to be managed with slow titration to maintenance dosing, which will be tested in Phase III.
BIO Notebook: Venture Capital Musical Chairs, Pfizer’s Financing Strategy, And Boehringer on Being The Early Bird
Plus, Roche talks about why it wants to partner with firms that have machine learning expertise as the BIO International Convention continues in Boston.